Articles tagged "Kidney transplantation"

2022 American Transplant Congress
Blood Transcriptomes of Covid-19 Infected Kidney Recipients Demonstrate Frequent and Persistent Sars-cov-2 Virome Gene Expression
Z. Sun¹, M. M. Rana², A. C. Reghuvaran³, Y. A. Azzi⁴, G. Carrara⁵, S. Hartzell⁶, S. Kulkarni³, W. Zhang⁶, K. Banu³, P. Heeger⁶, E. Akalin⁴, P. Cravedi⁶, Z. Zhang⁷, M. C. Menon³
¹Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, ²Infectious Disease Director, Icahn School of Medicine at Mount Sinai, New York, NY, ³Nephrology, Yale University, New Haven, CT, ⁴Nephrology, Montefiore Medical Center, New York, NY, ⁵Clinical Research Coordinator, Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Kidney transplant recipients (KTRs) have poor outcomes vs non-KTRs with acute COVID-19. To provide insight into management of immunosuppression during acute COVID-19, we studied…
2022 American Transplant Congress
Alloreactive Regulatory T Cells Release Distinct Subpopulations of Extracellular Vesicles Bearing Immune Regulatory Proteins and the TCR/CD3 Complex Under Antigen Specific Stimulation
B. Schreiber, S. Tripathi, A. Sonawane, M. Blaser, S. Kuraoka, S. Singh, M. Aikawa, E. Aikawa, A. Chandraker
Brigham and Women's Hospital, Boston, MA
*Purpose: Extracellular vesicles (EVs) are vital mediators of intercellular communication, playing an important role in the immune synapse and the T cell response. However, regulatory…
2022 American Transplant Congress
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients
G. Osuchukwu¹, A. Trevino¹, L. Beretich², S. McCormick², N. Kaur², R. White², P. Gauthier²
¹Victoria Kidney and Dialysis Associates, Victoria, TX, ²Natera, Inc., Austin, TX
*Purpose: Continuous administration of immunosuppressive therapy (IST) is required to avoid allograft rejection in transplant recipients. However, these therapeutic interventions can lead to significant side…
2022 American Transplant Congress
Conversion from Immediate to Extended-Release Tacrolimus (LCP-Tac) Six Months After Renal Transplantation Optimizes Safety and Efficacy
S. P. Patel, F. Bartlett, T. Sprague, J. Newman, E. Andrade, N. Rao, N. Patel, D. Dubay, V. Rohan, M. Casey, D. Taber
MUSC Health, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for prevention of rejection in kidney transplant recipients (KTRs) that may have less variability and…
2022 American Transplant Congress
Low Fixed Tacrolimus Starting Dose and the Correlation with Renal Allograft Rejection
R. Davoudi, E. Kitchel, S. Lee, T. Tan, T. Sievers, S. Bunnapradist
David Geffen School of Medicine, Los Angeles, CA
*Purpose: Achieving a tacrolimus therapeutic trough concentration (C0) by post-operative day (POD) 3-7 has been associated with a reduced risk for rejection. Although FDA prescribing…
2022 American Transplant Congress
Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression
B. Sirandas, A. Chan, M. Eiting, T. Larson, C. Truax, L. Smith
University of Utah Health, Salt Lake City, UT
*Purpose: The demand for kidney transplant continues to rise, and limited supply has encouraged acceptance of marginal donor organs, such as those at risk for…
2022 American Transplant Congress
Patient Reported Outcomes Following Renal Transplantation: The Future of Holistic Post-Transplant Care
H. V. Spiers¹, S. Frame², R. Heape³, K. Clark², A. Altinar², L. Ross², H. Wells², A. Simpson³, J. Chilcot³, L. Hughes³, D. M. Summers¹, J. Weinman³, M. Hotopf³, A. J. Cronin²
¹Roy Calne Transplant Unit, Department of Transplantation, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Department of Nephrology and Transplantation, Guy’s and St. Thomas’ Hospital, London, United Kingdom, ³King's College London, London, United Kingdom
*Purpose: Patients with renal disease prioritise symptoms and functionality over the biochemistry and clinical guidelines, which clinicians traditionally rely on. Whilst kidney transplantation is expected…
2022 American Transplant Congress
Acute Tubular Injury and Necrosis Do Not Lead to Meaningful Elevations in Donor-Derived Cell-Free DNA (dd-cfDNA)
S. R. Allam¹, M. Cooper², D. Kumar³, T. Maw⁴, A. Wiseman⁵, P. Chuang⁶, G. Shekhtman⁷, N. Agrawal⁷, J. Zeng⁷, E. Huang⁸
¹Medical City Transplant Institute, Fort Worth, TX, ²Medstar Georgetown Transplant Institute, Washington, DC, ³Virginia Commonwealth University, Richmond, VA, ⁴University of Southern California, Los Angeles, CA, ⁵Centura Health, Denver, CO, ⁶Metrolina Nephrology, Charlotte, NC, ⁷CareDx, Brisbane, CA, ⁸Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Associations between non-rejection histologic diagnoses and dd-cfDNA have not been extensively characterized. We explored these associations in kidney transplant recipients enrolled in the Kidney…
2022 American Transplant Congress
Real-Life Prevention of Breakthrough SARS-CoV-2 Infections by mRNA Vaccines in Kidney Transplant Recipients vs Hemodialysis Patients
D. Rodríguez-Espinosa, E. Montagud-Marrahi, J. Cacho, C. Arana, N. Taurizano, E. Hermida, J. Del Risco, J. Casals, A. Rosario, E. Cuadrado, N. Rodríguez, I. Revuelta, B. Bayès, P. Ventura-Aguiar, F. Cofan, E. Poch, F. Oppenheimer, M. Vera, L. Rodas, F. Maduell, F. Diekmann, A. Cases, J. Broseta, D. Cucchiari
Nephrology and Renal Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain
*Purpose: The increased COVID-19 severity observed in kidney transplant recipients (KTR) has been widely reported. In addition, several studies have shown a reduced humoral and…
2022 American Transplant Congress
Kinetics of dd-cfDNA in Kidney Transplant Recipients Following Sars-CoV-2 Vaccination Booster Administration
N. M. Ali¹, S. Mehta¹, V. Tatapudi¹, A. Mattoo¹, I. Soomro¹, J. Benstein¹, H. Neumann¹, F. Zervou¹, J. Miles², R. Montgomery¹
¹Transplant Institute, NYU Langone Health, New York, NY, ²CareDx, Brisbane, CA
*Purpose: Evolving data suggests booster vaccine doses enhance the immunogenicity of SARS-CoV-2 vaccines in solid organ transplant recipients with higher IgG responses, neutralizing antibodies titers,…